Biocept, Inc.
BIOCQ · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -761.37% | -314.72% | -145.98% | -84.93% |
| EV / EBITDA | -1.84 | -1.05 | -0.12 | 0.06 |
| Quality | ||||
| ROIC | -32.00% | -35.21% | -68.18% | -27.82% |
| Gross Margin | -332.94% | -349.93% | 141.88% | -473.58% |
| Cash Conversion Ratio | 0.85 | 0.87 | 0.23 | 0.40 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | 1,002,227.91% |
| Free Cash Flow Growth | 49.36% | -43.56% | 1.22% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.70 | -0.74 | 0.04 | 0.60 |
| Interest Coverage | -122.28 | -154.30 | -395.81 | -195.33 |
| Efficiency | ||||
| Inventory Turnover | 4.63 | 4.30 | 5.69 | 3.04 |
| Cash Conversion Cycle | 89.91 | 124.07 | -34.83 | 553.83 |